DNTH103 for Myasthenia Gravis
(MAGIC Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications, but you cannot have used Rituximab within 6 months or IVIg and plasma exchange within 4 weeks before starting the trial.
Recent advances in drug therapy for myasthenia gravis have significantly improved the quality of life for many patients, reducing complications and hospitalizations. While specific data on DNTH103 is not provided, the approval of similar treatments like complement and FcRN inhibitors by the FDA suggests potential effectiveness in managing the condition.
12345DNTH103 is unique because it is an antisense oligonucleotide that targets acetylcholinesterase (AChE) mRNA, potentially reducing AChE activity and improving muscle function in myasthenia gravis. This mechanism is different from other treatments like pyridostigmine, which directly inhibits AChE, and eculizumab, which targets the complement system.
678910Eligibility Criteria
Adults aged 18-75 with generalized myasthenia gravis (gMG), a muscle weakness condition, can join this trial. They must have an MG-ADL score of 6+, be AChR antibody positive, and fall within the MGFA Class II-Iva. Participants need to agree to contraception if applicable and should weigh between 40-120 kg.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Randomized, blinded, controlled treatment (RCT)
Participants receive either DNTH103 or placebo to evaluate safety, tolerability, pharmacometrics, and efficacy
Open-label extension (OLE)
Eligible participants may opt into continuation of treatment with DNTH103 long-term
Safety follow-up
Participants are monitored for safety and effectiveness after treatment